Antidepressant treatment increases quality of life in patients with chronic renal failure

Creative Commons License

Kalender B., Ozdemir A. C., Yalug I., Dervisoglu E.

RENAL FAILURE, cilt.29, sa.7, ss.817-822, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 7
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1080/08860220701573517
  • Dergi Adı: RENAL FAILURE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.817-822
  • Kocaeli Üniversitesi Adresli: Evet

Özet

To evaluate the effect of citalopram treatment on quality of life (QoL) and depression in 141 patients with chronic renal failure (CRF), QoL was measured by means of the Short Form 36 (SF-36). Patients diagnosed with depression were treated with citalopram for eight weeks and evaluated for the effect of treatment on depressive symptoms and QoL. Thirty-four of 141 patients (24.1 %) had depression and treatment with citalopram decreased Beck Depression Inventory Scores and increased the emotional role limitation and the mental health subscale scores of SF-36. This study suggests that citalopram can treat depression and improve QoL in patients with CRF.